UK markets close in 20 minutes

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
136.66-2.31 (-1.66%)
As of 11:08AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 13.98B
Enterprise value 13.37B
Trailing P/E 56.26
Forward P/E 26.95
PEG ratio (5-yr expected) 0.46
Price/sales (ttm)7.44
Price/book (mrq)6.26
Enterprise value/revenue 7.09
Enterprise value/EBITDA 37.36

Trading information

Stock price history

Beta (5Y monthly) 0.28
52-week change 336.38%
S&P500 52-week change 322.64%
52-week high 3148.37
52-week low 389.04
50-day moving average 3136.39
200-day moving average 3121.00

Share statistics

Avg vol (3-month) 3885.57k
Avg vol (10-day) 3801.11k
Shares outstanding 5100.58M
Implied shares outstanding 6101.51M
Float 898.29M
% held by insiders 11.00%
% held by institutions 194.71%
Shares short (15 Apr 2024) 42.02M
Short ratio (15 Apr 2024) 42.26
Short % of float (15 Apr 2024) 42.35%
Short % of shares outstanding (15 Apr 2024) 42.01%
Shares short (prior month 15 Mar 2024) 42.48M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 429 Dec 1995
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 13.23%
Operating margin (ttm)29.17%

Management effectiveness

Return on assets (ttm)8.78%
Return on equity (ttm)12.68%

Income statement

Revenue (ttm)1.89B
Revenue per share (ttm)19.32
Quarterly revenue growth (yoy)25.00%
Gross profit (ttm)N/A
EBITDA 416.1M
Net income avi to common (ttm)249.7M
Diluted EPS (ttm)2.47
Quarterly earnings growth (yoy)66.00%

Balance sheet

Total cash (mrq)1.03B
Total cash per share (mrq)10.37
Total debt (mrq)460.4M
Total debt/equity (mrq)20.63%
Current ratio (mrq)2.45
Book value per share (mrq)22.61

Cash flow statement

Operating cash flow (ttm)389.9M
Levered free cash flow (ttm)405.08M